AstraZeneca Results Presentation Deck
H1 2021: growth profile enhanced
Oncology and New CVRM drove growth
Oncology
New CVRM
Respiratory &
Immunology
Other medicines
Total revenue
excl. vaccine
Pandemic COVID-19
vaccine
Total revenue
Growth across
disease areas
H1 ‘21 growth
$m
%
6,360
2,731
2,970
14,371
1,169
2,310 (6)
15,540
15
Total revenue at actual exchange rates; changes at CER.
8
16
6
9
18
ratio
%
41
18
19
15
92
100
Q2 '21 growth
$m
%
3,337
1,425
1,424
1,140
7,326
894
8,220
14
16
21
(8)
12
25
ratio
%
41
17
17
14
89
11
100
EM¹
- EM excl. China
- China
US
Europe
Established
rest of world
Total revenue
Growth across
geographies
growth
%
H1‘21
$m
5,459
2,250
3,209
4,834
3,261
1,986
15,540
21
36
11
16
21
13
18
Total revenue at actual exchange rates; changes at CER. 1. Emerging markets.
ratio
%
35
14
21
31
21
13
100
Q2 '21
$m
2,868
1,337
1,531
2,524
1,715
1,113
8,220
growth
%
32
63
12
21
24
20
25
ratio
%
35
16
19
31
21
14
100
BView entire presentation